A Study of Isoprinosine in Patients With Lymph Node Disease

Not Applicable

Completed

• Conditions: Lymphatic Disease; HIV Infections

• Registration Number: NCT00002297
• Lead Sponsor: Newport Pharmaceuticals International

Brief Summary

The objectives of this study are to determine the effects of isoprinosine in patients diagnosed as having unexplained generalized lymphadenopathy. Variables to be examined will include:

Signs and symptoms:

* Lymphadenopathy.

* Fever.

* Weight loss.

* Occurrence of opportunistic infections.

Cell-mediated immune system parameters:

* T-helper cell (OKT4) numbers and proportions.

* T-suppressor cell (OKT8) numbers and proportions.

* Natural killer (NK) cell activity.

* Lymphocyte blastogenic response to phytohemagglutinin (PHA).

* Lymphocyte blastogenic response to pokeweed mitogen (PWM).

* Immunoglobulin (IgG, IgA, IgM, IgE, IgD) profile.

* Circulating immune complexes. Infections characteristically associated with AIDS, such as Candida albicans, Pneumocystis carinii pneumonia, Cytomegalovirus, Herpes simplex, Cryptococcus, Histoplasma, Toxoplasma, Cryptosporidium, Mycobacterium avium- intracellulare, Legionella, and Isospora.

Safety parameters:

* Blood chemistry including serum uric acid (PurposeA-12).

* Complete blood count (CBC).

* Platelet count.

Detailed Description

Not available

Study Timeline

• Status Verified: 1989-06
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Newport Pharmaceuticals International Inc; 🇺🇸 Laguna Hills, California, United States